Maryland Oncology Hematology, P.A.
Columbia, Maryland, United States
Cancer treatment center in Columbia, Maryland
10710 Charter Dr #G020, Columbia, MD 21044
About Maryland Oncology Hematology, P.A.
"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
14
Novartis Pharmaceuticals
12
US Oncology Research
8
Bristol-Myers Squibb
7
Pfizer
7
Celgene
5
Eli Lilly and Company
5
Janssen Research & Development, LLC
5
Amgen
4
Seagen Inc.
4
AVEO Pharmaceuticals, Inc.
3
Clinical Trials at Maryland Oncology Hematology, P.A.
During the past decade, Maryland Oncology Hematology, P.A. conducted 78 clinical trials. In the 10-year time frame, 78 clinical trials started and 55 clinical trials were completed, i.e. on
average, 70.5% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 33 clinical trials were completed. i.e. 126.9%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
1999-12-01
Unknown status
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
2000-12-04
2014-03-17
Completed
2,104
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
2001-01-01
Unknown status
Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer
2001-11-01
Unknown status
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
2002-08-01
2005-12-01
Unknown status
250
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
2002-06-01
2006-01-01
Completed
865
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
2002-05-01
2005-03-01
Completed
612
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
2004-02-01
2012-11-01
Completed
3,397
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Maryland Oncology Hematology, P.A." #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Novartis Pharmaceuticals" with 12 trials
sponsored, "US Oncology Research" with 8 trials sponsored, "Bristol-Myers Squibb" with 7 trials sponsored and "Pfizer"
with 7 trials sponsored. Other sponsors include 88 different institutions and
companies that sponsored additional 63 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Oncology Hematology, P.A."
#1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "ARMO BioSciences" with 2 trials as a collaborator. Other collaborators include 33 different institutions and companies that were
collaborators in the rest 36 trials.
Clinical Trials Conditions at Maryland Oncology Hematology, P.A.
According to Clinical.Site data, the most researched conditions in "Maryland Oncology Hematology, P.A." are
"Breast Cancer" (19 trials), "Metastatic Breast Cancer" (9 trials), "Ovarian Cancer" (8 trials), "Carcinoma, Non-Small-Cell Lung" (6 trials) and "Non-Small Cell Lung Cancer" (6 trials). Many other conditions were trialed in "Maryland Oncology Hematology, P.A." in a lesser frequency.
Clinical Trials Intervention Types at Maryland Oncology Hematology, P.A.
Most popular intervention types in "Maryland Oncology Hematology, P.A." are "Drug" (131 trials), "Biological" (16 trials), "Other" (5 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (15 trials), "Paclitaxel" (11 trials), "Carboplatin" (9 trials), "Docetaxel" (9 trials) and "Cyclophosphamide" (6 trials). Other intervention names were less common.
Clinical Trials Genders at Maryland Oncology Hematology, P.A.
The vast majority of trials in "Maryland Oncology Hematology, P.A." are
102 trials for "All" genders, 24 trials for "Female" genders and 15 trials for "Male" genders.
Clinical Trials Status at Maryland Oncology Hematology, P.A.
Currently, there are NaN active trials in "Maryland Oncology Hematology, P.A.".
undefined are not yet recruiting,
21 are recruiting,
33 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 65 completed trials in Maryland Oncology Hematology, P.A.,
undefined suspended trials,
and 15 terminated clinical trials to date.
Out of the total trials that were conducted in Maryland Oncology Hematology, P.A., 16 "Phase 1"
clinical trials were conducted, 52 "Phase 2" clinical
trials and 65 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 5 trials, and there were
also 1 trials that are defined as “Not Applicable".